Most neuromyelitis optica spectrum disorder (NMOSD) patients who start taking Enspryng (satralizumab) remain free of relapses for at…
Articles by Margarida Maia, PhD
People who develop neuromyelitis optica spectrum disorder (NMOSD) at an older age are more likely to experience spinal cord…
Tocilizumab, an anti-inflammatory medication used off-label for neuromyelitis optica spectrum disorder (NMOSD), can help prevent relapses (flare-ups) and ease…
Health Canada has approved Uplizna (inebilizumab-cdon) to treat adults in the country with neuromyelitis optica spectrum disorder (NMOSD)…
About 1 in 10 people who are hospitalized for neuromyelitis optica spectrum disorder (NMOSD) are readmitted to the hospital…
People with a genetic makeup that causes them to be more susceptible to COVID-19 are nearly five times as likely…
The U.S. Food and Drug Administration (FDA) has asked for modifications to the risk evaluation and mitigation strategy — known…
Neuromyelitis optica spectrum disorder (NMOSD) is associated with a faster loss of white matter volume in the brain, but…
Nearly two in 10 neuromyelitis optica spectrum disorder (NMOSD) patients develop new asymptomatic brain and spinal cord lesions during…
Neuromyelitis optica spectrum disorder (NMOSD) patients have significantly poorer nutritional status than healthy people which is associated with worse…